25 March 2026
Proveca submits a New Drug Application to the U.S. Food and Drug Administration
This press release is intended for investors only … Proveca Ltd submits a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Aqumeldi® (enalapril maleate), a prescription drug. The submission is made for the following indications: • Treatment of...
23 March 2026
Proveca and BCWorld Healthcare announce the launch of the first licensed product in South Korea
Press release intended for investors only … 20 March 2026 – Proveca and BCWorld Healthcare (hereinafter BCW) are pleased to announce the launch of Sialanar® (glycopyrronium) in South Korea today. Sialanar® is the first licensed product approved in South Korea for the symptomatic...
10 March 2026
Monument Therapeutics announces first patient dosed in clinical trial of MT1988 in patients at clinical high risk for psychosis
Manchester, UK, March 10, 2026 - Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis. The study is being conducted...
23 February 2026
Biofortuna pioneers new robotic system for diagnostic tests
A North Wales biotechnology company has developed a new robotic dispensing system designed to improve the production of diagnostic testing devices used to detect conditions including cancer. Deeside-based Biofortuna secured £225,000 through the Welsh Government’s SMART Flexible...
11 February 2026
Proveca announces exclusive worldwide development and license agreement with Catalent for its Zydis® ODT technology for use with Glycopyrrolate
This press release is intended for investors only. 10th February 2026 - Proveca, a pharmaceutical company specialising in medicines for children, announced today that it has entered into an exclusive worldwide development and license agreement with Catalent, a leading global...
21 January 2026
QV Bioelectronics receives £4.5m boost for implantable brain cancer therapy
A Cheshire-based medtech business has secured £4.5m of investment and grant funding to revolutionise treatment for the most common type of primary brain cancer in adults. The investment round was led by PXN Ventures, which launched following the merger between Praetura Ventures...
10 December 2025
Oxford BioTherapeutics enters into strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer
• Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets … • The agreement - OBT's second high-profile pharma collaboration this year - reflects the strong validation of...
9 December 2025
Welsh Government Ministers visit Biofortuna to celebrate innovation and skills development
Biofortuna, a leading diagnostics manufacturer and laboratory services provider, welcomed Welsh Government Ministers Ken Skates MS and Jack Sargeant MS on Monday (8th December) to demonstrate how the Deeside-based CDMO is playing a pivotal role in the early detection of disease.
24 November 2025
MAXWELLIA - Pharmacist and ‘OTC innovator’ named North West Innovation Entrepreneur of the Year
Pharmacist and founder of healthcare brand Maxwellia, Anna Maxwell, has been named Innovation Entrepreneur of the Year for the North West at the Great British Entrepreneur Awards. Her work involves ‘switching’ UK prescription (Rx) medicines to launch as over the counter (OTC)...
13 October 2025
New prescription-strength pain relief hits high street chemists, hailed as ‘game-changer’ by pharmacists
Alderley Park, Cheshire, UK – A new anti-inflammatory pain relief treatment available from pharmacies, is being described as a ‘game-changer’ for the millions of people who suffer short-term back, muscle and joint pain every year in the UK. … Naprosyn® Pain Relief is the first...